Peakdale Molecular - News

ENBIOTEC AND PEAKDALE MOLECULAR ENTER AGREEMENT TO DEVELOP NUCLEAR RECEPTOR BASED LEAD COMPOUNDS.

Chapel-en-le-Frith, UK, 1st May 2007

Peakdale Molecular Ltd., has entered into an agreement with EnBioTec Laboratories Co., Ltd., based in Tokyo, Japan, to co-develop nuclear receptor based lead compounds for drug discovery.

EnBioTec Laboratories has developed the Receptor Cofactor Assay System (RCAS) to investigate the interactions between nuclear hormone receptors, co-factors, and ligands. The system is cell-free, highly sensitive and is able to distinguish between agonist and antagonist compounds.

Peakdale Molecular will provide a targeted set of compounds for RCAS and functional assay testing and will work with EnBioTec to custom synthesize novel compounds based on the subsequent test results.

Commenting on the collaboration, Ray Fisher, CEO of Peakdale Molecular said "We have some outstanding novel synthetic chemistry to offer this collaboration and are also excited about the downstream medicinal chemistry services that Peakdale will provide following the RCAS screening process"

Peakdale Molecular offers a range of products and services to the pharmaceutical and biotechnology industry to accelerate drug discovery through novel and creative chemistry.

For more information about enbiotec, please visit the Enbiotec website

FOR MORE INFORMATION REGARDING THIS NEWS
ARTICLE PLEASE CONTACT

Sarah Barratt
Marketing Executive
Peakdale Molecular Ltd
01298 816 700
sarah.barratt@peakdale.co.uk